公开(公告)号：US11756651B2

公开(公告)日：2023-09-12

申请号：US16767366

申请日：2018-12-21

申请人： NANTOMICS, LLC ,  NANTBIO, INC. ,  NANT HOLDINGS IP, LLC

发明人： Kevin B. Givechian ,  Kamil A. Wnuk ,  Chad Garner ,  Stephen Charles Benz ,  Hermes J. Garban ,  Shahrooz Rabizadeh ,  Kayvan Niazi ,  Patrick Soon-Shiong

IPC分类号： G16B25/10 ,  C12Q1/6886

CPC分类号： G16B25/10 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/158

摘要： An immune gene expression signature is associated with favorable clinical features in Treg-enriched tumor samples and can be used to predict immunogenicity of a tumor, overall survival, and/or chemosensitivity.

公开(公告)号：US20230377686A1

公开(公告)日：2023-11-23

申请号：US18359437

申请日：2023-07-26

申请人： Nantomics LLC ,  NantBio, Inc. ,  Nant Holdings IP, LLC

发明人： Kevin B. Givechian ,  Kamil A. Wnuk ,  Chad Garner ,  Stephen Charles .Benz ,  Hermes J. Garban ,  Shahrooz Rabizadeh ,  Kayvan Niazi ,  Patrick Soon-Shiong

IPC分类号： G16B25/10 ,  C12Q1/6886

CPC分类号： G16B25/10 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/158

摘要： An immune gene expression signature is associated with favorable clinical features in Treg-enriched tumor samples and can be used to predict immunogenicity of a tumor, overall survival, and/or chemosensitivity.

公开(公告)号：US20190233900A1

公开(公告)日：2019-08-01

申请号：US16264379

申请日：2019-01-31

申请人： Nantomics, LLC ,  NantBio, Inc.

发明人： Kevin B. Givechian ,  Chad Garner ,  Hermes J. Garban ,  Shahrooz Rabizadeh ,  Patrick Soon-Shiong

IPC分类号： C12Q1/6886 ,  A61K33/243

CPC分类号： C12Q1/6886 ,  A61K33/243 ,  C12Q2600/106 ,  C12Q2600/112 ,  C12Q2600/156 ,  C12Q2600/158

摘要： Compositions, methods, and uses of de novo pyrimidine synthesis pathway element, CAD, and optionally a second gene in a nucleotide excision repair pathway, POLD2 in determining a predicted survival rate, predicted responsiveness to a cisplatin-based chemotherapy of a patient diagnosed with bladder urothelial carcinoma are provided.